Loading stock data…
COLL
$34.32+0.59 (+1.75%)
After Hours$34.32+0.00 (+0.00%)· Last close May 1
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Collegium Pharmaceutical, Inc. in the Healthcare sector is trading at $34.32. The stock is currently 32% below its 52-week high of $50.79, remaining 12.9% below its 200-day moving average. Technical signals show neutral RSI of 42 and bullish MACD crossover, explaining why COLL maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$34.32
Potential Upside
19.5%
Whystock Fair Value$41.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$54.17+57.8%
Range$44.00 – $60.00
Fundamentals
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.55
Beta
Defensive asset. Lower volatility than the S&P 500.
0.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.84%
Volume
Today's trading volume
300,793
Recent News
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical Sets 2026 Revenue Outlook, Details $650M AZSTARYS Deal at Needham Conference
Collegium Pharmaceutical (NASDAQ:COLL) outlined its 2026 outlook and discussed its planned acquisition of the ADHD treatment AZSTARYS during a fireside chat at Needham & Company’s 25th Annual Healthcare Conference. President and CEO Vikram Karnani and Chief Financial Officer Colleen Tupper spoke
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
How The Collegium Pharmaceutical (COLL) Narrative Is Evolving On A Modest Target Price Shift
The latest update around Collegium Pharmaceutical centers on a modest US$3 lift in the price target, while the fair value estimate holds at US$54.17. Bullish and bearish analysts are reading that same move in very different ways, with some seeing steady conviction in the existing thesis and others flagging limited upside without clearer new catalysts. As you read on, you will see how to interpret these shifts and track the evolving story around Collegium from here. Analyst Price Targets don't...
3 Cash-Producing Stocks Walking a Fine Line
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.